As part of her autumn tour, the Federal Minister of Education and Research, Bettina Stark-Watzinger, visited the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection
Please use this image only in connection with this press release.
When you hear about tuberculosis, the first thing that comes to mind is lung disease. However, almost 30 percent of tuberculosis cases in Germany affect extrapulmonary organs. The disease, triggered
Between 10 and 20 million people worldwide are infected with hepatitis D virus (HDV). HDV infection is always associated with hepatitis B virus infection. So far there has been no satisfactory
Prof. Oliver Cornely, infectiologist and coordinator of the DZIF Clinical Trial Unit at the University Hospital Cologne, has been awarded the Johann Lucas Schönlein Plaque by the German-speaking
Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the
In the early 20th century, French scientists Albert Calmette and Camille Guérin developed a vaccine from the bovine tuberculosis bacterium Mycobacterium bovis, which was named BCG (Bacillus Calmette
Finding active agents against SARS-CoV-2 and other coronaviruses—this goal has been pursued by DZIF scientist Prof Thomas Schulz and his team at Hannover Medical School (MHH) since the virus first
Besides SARS-CoV and SARS-CoV-2, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is among the highly pathogenic coronaviruses that can lead to severe respiratory disease and death. It is
Worldwide, 880,000 people die each year as a result of infection with the hepatitis B virus (HBV). Antiviral drugs that can suppress replication of the virus are available. However, these must be
The DZIF Academy is pleased to open the call for applications for two prizes in 2022: the DZIF Prize for Fundamental Translational Infection Research and the DZIF Prize for Clinical Translational
